Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data

Abstract

BackgroundThere exist several predictive risk models for cardiovascular disease (CVD), including some developed specifically for patients with type 2 diabetes mellitus (T2DM). However, the models developed for a diabetic population are based on information derived from medical records or laboratory results, which are not typically available to entities like payers or quality of care organizations. The objective of this study is to develop and validate models predicting the risk of cardiovascular events in patients with T2DM based on medical insurance claims data.MethodsPatients with T2DM aged 50 years or older were identified from the Optum™ Integrated Real World Evidence Electronic Health Records and Claims de-identified database (10/01/2006–09/30/2016). Risk factors were assessed over a 12-month baseline period and cardiovascular events were monitored from the end of the baseline period until end of data availability, continuous enrollment, or death. Risk models were developed using logistic regressions separately for patients with and without prior CVD, and for each outcome: (1) major adverse cardiovascular events (MACE; i.e., non-fatal myocardial infarction, non-fatal stroke, CVD-related death); (2) any MACE, hospitalization for unstable angina, or hospitalization for congestive heart failure; (3) CVD-related death. Models were developed and validated on 70% and 30% of the sample, respectively. Model performance was assessed using C-statistics.ResultsA total of 181,619 patients were identified, including 136,544 (75.2%) without prior CVD and 45,075 (24.8%) with a history of CVD. Age, diabetes-related hospitalizations, prior CVD diagnoses and chronic pulmonary disease were the most important predictors across all models. C-statistics ranged from 0.70 to 0.81, indicating that the models performed well. The additional inclusion of risk factors derived from pharmacy claims (e.g., use of antihypertensive, and use of antihyperglycemic) or from medical records and laboratory measures (e.g., hemoglobin A1c, urine albumin to creatinine ratio) only marginally improved the performance of the models.ConclusionThe claims-based models developed could reliably predict the risk of cardiovascular events in T2DM patients, without requiring pharmacy claims or laboratory measures. These models could be relevant for providers and payers and help implement approaches to prevent cardiovascular events in high-risk diabetic patients.Electronic supplementary materialThe online version of this article (10.1186/s12933-018-0759-z) contains supplementary material, which is available to authorized users.

Electronic Medical Record–Based Case Phenotyping for the Charlson Conditions: Scoping Review

“…The most commonly linked inpatient care data came from the Electronic Medical Records and Genomics (eMERGE) consortium [ 293 ], which provided additional validation between clinical documentation and scientific (ie, genomic) observation. These data linkage studies were employed for epidemiological analyses (improved accuracy of incidence and prevalence estimates) of diseases at the population level [ 83 , 96 , 212 ].…”

Cholesterol levels and development of cardiovascular disease in Koreans with type 2 diabetes mellitus and without pre-existing cardiovascular disease

“…However, indication for starting statin therapy should also be related to the progression of atherosclerosis or clinical event regardless on a level of baseline cholesterol [16–18]. For the prediction of MI or stroke, the area under the curve of LDL-C alone was low (data not shown), suggesting that including other potential risk factors such as smoking, BP, or family history of premature vascular disease to the risk model would be beneficial for a better risk prediction of CVD rather than LDL-C alone [18, 19]. Statins might be employed in patients without CVD but with elevated cholesterol and/or multiple atherosclerotic risk factors.…”

A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe

“…History of established CVD is one of the most widely recognised and important predictors of future major adverse cardiovascular events (MACE) [59]. Similarly, both decreased estimated glomerular filtration rate (eGFR) and albuminuria are strong independent predictors of MACE in patients with T2D [60]. Finally, there is evidence to suggest that early-onset T2D represents an aggressive form of the disease in terms of cardiovascular risk [61], reflected in the fact that patients with a younger age at diagnosis have a much higher cardiovascular risk than that of age-matched controls [62].…”